Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT

Journal of Viral Hepatitis

Volumn 11, Issue 6, 2004, Pages 552-558

  Sarin, S K ^a   Sandhu, B S ^a   Sharma, B C ^a   Jain, M ^a   Singh, J ^a   Malhotra, V ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

Antiviral drugs; Chronic hepatitis; Cirrhosis; Hepatitis B virus; Viral replication; YMDD

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CORTICOSTEROID; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ACUTE HEPATITIS; ADULT; ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPETENCE; IMMUNOMODULATION; LIVER FAILURE; LIVER FUNCTION TEST; MALE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SEROCONVERSION; SINGLE BLIND PROCEDURE; TH1 CELL;

ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MUTATION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 8444226035     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00542.x     Document Type: Conference Paper

References (26)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8(Suppl.): 518-520.
2. Lok AS, Heathcote EJ, Hoofnagel JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-1853.
3. Liaw YF, Tai DI, Chu CM, Chen IJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496.
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129-1133.
5. Lok ASF, McMohan BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225-1241.
6. Core working party for Asia-Pacific consensus on Hepatitis B and C. Consensus statement on the prevention and management of hepatitis B and hepatitis C in the Asia Pacific region. J Gastroenterol Hepatol 2000; 15: 825-841.
7. Liaw YF, Leung NWY, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-180.
8. Alward WLM, Mc Mahon BJ, Hall DB, Heyward WL, Francis DP, Bender TR. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151: 604-609.
9. Alter HJ, Seeff LB, Kaplan PM et al. Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needle-stick exposure. N Engl J Med 1976; 295: 909-913.
10. Sarin SK, Singhal AK. Hepatitis B in India: therapeutic options and prevention strategies - consensus statements. Ind J Gastroenterol 2000; 19(Suppl. 3): 654-666.
11. Okada K, Kamlyama I, Inomata M, Imai M, Miyakawa M, Mayuni M. e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294: 746-749.
12. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol 1998; 13: 14-20.
13. Liaw YF, Tsai SL, Ehien RN, Chien RN, Yeh CT, Chu CM. Prednisolone priming enhances Th-1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology 2000; 32; 604-609.
14. Chisari FV, Ferari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
15. Chien RN, Liaw YF, Atkins M for the Asian Hepatitis Lamivudine Trial Group. Pre-therapy alanine aminotransferase level as a determinant for HBeAg seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-774.
16. Boni C, Bertoletti A, Penna A et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968-975.
17. Honkoop P, deMan RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-639.
18. Ishak K, Baptista A, Bianctu L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699.
19. Wakil SM, Kazim SN, Khan LA et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol 2002; 68: 311-318.
20. Perrillo RP. Short-term corticosteroid in combination with lamivudine: A case of Déjà vu? Hepatology 2000; 32: 663-665.
21. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Scu USA 1986; 83: 1627-1631.
22. Chou CK, Want LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992; 16: 13-18
23. Atkins M, Hunt CM, Brown N et al. Clinical significance of YMDD mutant hepatitis B virus in a large cohort of lamivudine-treated hepatitis B patients. Hepatology 1998; 28(Suppl.): 319A.
24. Hoofnagle JH, Davis GL, Pappas SC et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1986; 104: 12-17.
25. Lai CL, Chien RN, Leung NWY et al. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.
26. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-806.